Because AOD-9604 works peripherally on fat tissue through beta-3 adrenergic receptors without affecting central appetite pathways, there is no adaptation of hunger-regulating systems and therefore no rebound effect when stopping
Developed by Theratechnologies Inc., it underwent phase II trials in the mid-2000s for GH deficiency (GHD) and HIV lipodystrophy but was discontinued, with reported reasons including hypersensitivity reactions, including an anaphylaxis-like reaction in one trial participant Wong et al (2008) [Note: Abstract only
GHK-Cu is a naturally occurring copper-binding peptide studied for its role in cellular signaling pathways related to tissue support, extracellular matrix biology, and gene expression
Read clinical review A clinician-reviewed guide to the losartan and saw palmetto interaction, covering mechanism, monitoring, and what to do if you are already taking both
Eur Respir J 1995;8:48391